Dilip Shanghvi

Last updated on 2015-03-06T08:47+0300.

About this image

sign

Quotes... Extracted quotes from

Dilip Shanghvi said : “So, that's broadly our understanding. So, we currently don't have any facility which we are looking at for producing vaccines,” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi said : “We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars,” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi noted : “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi said : “So, that’s broadly our understanding. So, we currently don’t have any facility which we are looking at for producing vaccines,” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi said : “We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars,” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi noted : “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi said : “While our India business continues to outperform the average industry growth, our global specialty sales have continued to show an improving trend. Global Ilumya sales for the year have grown by 51 per cent to $143 million,” External link

economictimes Thursday, May 27, 2021 3:45:00 PM EAT

Dilip Shanghvi said : “Our Q3 performance reflects continued profitable business growth in a market that is gradually recovering from the impact of the global pandemic,” “Most of our businesses have done well over the third quarter last year” External link

Hindu Saturday, January 30, 2021 4:15:00 AM EAT

Dilip Shanghvi said : "It is a key determinant of the future growth and profitability of the specialty initiative. We expect to continue to invest in specialty R&D in the coming years as we progress further in building the specialty business," "Our R&D investments for the year were approximately Rs 20 billion. We continue to be disciplined in identifying future R&D projects for the US generics market and the focus is on developing differentiated generics. Investments for developing the long-term specialty pipeline are expected to continue" External link

siliconindia Monday, September 28, 2020 7:53:00 AM EAT

Dilip Shanghvi said : "We have also recently entered into an exclusive licensing and distribution agreement with Hikma Pharmaceuticals PLC for commercialisation of Ilumya in the Middle East and North Africa (MENA) region," External link

business-standard Sunday, September 27, 2020 10:29:00 AM EAT

Dilip Shanghvi said : "We expect this momentum to continue over the next few years, although the Covid-19 pandemic and lockdowns may throw up some uncertainties in the near-term," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : "We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : "Sun Pharma's strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : “We expect this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : “We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : “Sun Pharma’s strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : "We expect this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : "We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : "Sun Pharma's strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : “We have not lost market share in any of the key products in the US or other markets. We witnessed the impact of lockdown on our US specialty business,” External link

business-standard Saturday, August 1, 2020 1:08:00 AM EAT

Dilip Shanghvi said : "Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients," "Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients," External link

timesofindia Friday, May 29, 2020 2:46:00 PM EAT

Dilip Shanghvi said : “We are committed to addressing these observations promptly,” External link

business-standard Thursday, February 6, 2020 10:04:00 PM EAT

Dilip Shanghvi said : “The focus is on developing relations with important players in that market (China) for our specialty products, and some generic products in which we do not expect much competition. As we continue to get approvals, China and Japan will become increasingly important” External link

business-standard Friday, November 8, 2019 12:53:00 AM EAT

Dilip Shanghvi said : “These are mostly products we are developing for other markets. Looking at the size of these markets, we do not rule out developing something specific for them,” External link

business-standard Friday, November 8, 2019 12:53:00 AM EAT

Dilip Shanghvi said : "We continue to focus on cost savings and efficiency improvement to align our generic business with the changing industry dynamics," External link

irishsun Thursday, November 7, 2019 4:06:00 PM EAT

Dilip Shanghvi said : "We continue to focus on cost savings and efficiency improvement to align our generic business with the changing industry dynamics," External link

business-standard Thursday, November 7, 2019 3:49:00 PM EAT

Dilip Shanghvi said ( about China Hong Kong ) : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and specialty portfolio. With more than 65 per cent generics penetration, China represents a significant opportunity for generic pharmaceutical companies,” External link

business-standard Wednesday, November 6, 2019 12:14:00 PM EAT

Dilip Shanghvi said : "This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio" External link

economictimes Monday, August 19, 2019 8:57:00 AM EAT

Dilip Shanghvi said : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio. With more than 65% generics penetration, China represents a significant opportunity for generic pharmaceutical companies,” External link

business-standard Friday, August 16, 2019 11:12:00 PM EAT

Dilip Shanghvi said : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio” External link

financialexpress Friday, August 16, 2019 9:04:00 PM EAT

Dilip Shanghvi said : "This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio" External link

business-standard Friday, August 16, 2019 8:05:00 PM EAT

Dilip Shanghvi said : "This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline," "CSIR-IICT is well-known for its high-quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction," External link

business-standard Wednesday, August 14, 2019 12:49:00 PM EAT

Dilip Shanghvi said : “We have recorded growth across most of the markets for the quarter and our performance is in line with our full-year guidance. We are consistently focusing to ensure reasonable returns for our generics business. At the same time, we continue our unwavering efforts on building the specialty business,” External link

business-standard Tuesday, August 13, 2019 11:28:00 PM EAT

Dilip Shanghvi said : "We will look for a fresh recruitment for the branded business development function...," External link

business-standard Tuesday, August 13, 2019 8:30:00 PM EAT

Dilip Shanghvi said : "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance," "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance. We are consistently focusing on improving our efficiencies and cost structure to ensure reasonable returns for our generics business," External link

irishsun Tuesday, August 13, 2019 6:57:00 PM EAT

Dilip Shanghvi said : "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance," "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance. We are consistently focusing on improving our efficiencies and cost structure to ensure reasonable returns for our generics business," External link

business-standard Tuesday, August 13, 2019 5:28:00 PM EAT

Dilip Shanghvi said : "At the same time, we continue our unwavering efforts on building the specialty business and are encouraged by the potential of one of our pre-clinical research molecules which is likely to enter clinical trials next year," External link

business-standard Tuesday, August 13, 2019 5:28:00 PM EAT

Dilip Shanghvi said : "We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need," External link

business-standard Thursday, June 27, 2019 7:09:00 PM EAT

Dilip Shanghvi said : "In spite of the one-time impact for India business, our full year sales have grown by double digits" External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi said : "At the same time, we are strengthening our core operations, optimising the cost structure and enhancing our overall efficiencies," External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi said : “In spite of the one-time impact for India business, our full-year sales have grown by double digits. We continue to focus on executing our global speciality strategy. Ilumya (psoriasis drug) is expected to gradually gain traction in the US in FY20, while Cequa’s (ophthalmic drug’s) launch is expected in the coming months. At the same time, we are strengthening our core operations, optimising the cost structure and enhancing our overall efficiencies,” External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi says : “It does require some additional skills beyond what a typical generic has,” External link

business-standard Thursday, May 23, 2019 1:35:00 AM EAT

Dilip Shanghvi says : “The performance of many large multinational Big Pharma companies has been mixed,” External link

business-standard Thursday, May 23, 2019 1:35:00 AM EAT

Dilip Shanghvi said : “If I look at outcome then clearly that investment hasn’t had a great outcome,” External link

business-standard Wednesday, May 8, 2019 12:54:00 PM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

financialexpress Monday, May 6, 2019 10:35:00 AM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

financialexpress Monday, May 6, 2019 10:35:00 AM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

economictimes Sunday, May 5, 2019 2:16:00 PM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

economictimes Sunday, May 5, 2019 2:16:00 PM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

financialexpress Sunday, May 5, 2019 7:13:00 AM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

financialexpress Sunday, May 5, 2019 7:13:00 AM EAT

Dilip Shanghvi said : "While we do not have access to the whistleblower documents, we have received information request from SEBI related to our 2004 FCCB issuance and also for our transactions with Aditya Medisales. " External link

business-standard Wednesday, February 13, 2019 1:09:00 PM EAT

Dilip Shanghvi said : "The Ilumya launch in US has been well received by doctors. We recently commercialised Xelpros in the US and are preparing to launch Cequa in the coming months," External link

business-standard Tuesday, February 12, 2019 6:02:00 PM EAT

Dilip Shanghvi said : "Our focus on execution is reflected in the Q3 performance" External link

business-standard Tuesday, February 12, 2019 6:02:00 PM EAT

Dilip Shanghvi said : “The points raised by securities firm pertains to many information which are sourced from public domain and has been around for some time. Some of the issues are not related to Sun Pharma, some are incorrect, and some are old, as old as 15 years,” External link

economictimes Thursday, December 13, 2018 7:15:00 AM EAT

Dilip Shanghvi said : “Sun Pharma has not been involved in any insider trading of the Ranbaxy case. However there was a minor issue on the procedural aspect of trading window during a holiday” External link

economictimes Thursday, December 13, 2018 7:15:00 AM EAT

Dilip Shanghvi said : “The reason why we are suffering is our inability to execute,” External link

economictimes Saturday, August 12, 2017 9:51:00 AM EAT

Dilip Shanghvi said : "Our Q1 performance was not good ... due to the combined impact of increasing investments in our global specialty business, temporary disruption in our India business due to GST implementation, a challenging U.S. generic pricing environment and the Modafinil settlement," External link

reuters-in Friday, August 11, 2017 3:35:00 PM EAT

Dilip Shanghvi said : "We have followed the law in the U.S. and all our people have followed appropriate behaviour," External link

reuters-in Tuesday, February 14, 2017 9:00:00 PM EAT

Dilip Shanghvi said : "Looking at the experience of some other sites, it may take more than three months post-reinspection to get clearance," External link

reuters Thursday, November 10, 2016 7:30:00 PM EAT

Dilip Shanghvi said : "The synergies from the Ranbaxy acquisition are gaining momentum and we are on track to achieve the targeted benefits," External link

reuters Thursday, November 10, 2016 7:30:00 PM EAT

Dilip Shanghvi said : "Sun Pharma is committed to growing our dermatology franchise, with tildrakizumab as our lead investigational compound. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are proud to be partnering with a regional leader in dermatology, like Almirall, to bring tildrakizumab to the European market," External link

prnewswire Wednesday, July 27, 2016 9:20:00 PM EAT

Dilip Shanghvi said : “At Sun Pharma we are focused on offering quality medicines to all our customers and patients worldwide. Under the dynamic leadership of Prime Minister Modi, we see an environment of technology-led innovation in India. It will enable us to bring innovative products meeting unmet medical needs of patients globally,” External link

expressindia Wednesday, June 8, 2016 8:27:00 AM EAT

Dilip Shanghvi said ( about Narendra Modi ) : “At Sun Pharma we are focused on offering quality medicines to all our customers and patients worldwide. Under the dynamic leadership of Prime Minister Modi, we see an environment of technology-led innovation in India. It will enable us to bring innovative products meeting unmet medical needs of patients globally,” External link

4-traders Wednesday, June 8, 2016 3:22:00 AM EAT

Dilip Shanghvi said : "The intention of the JV was to combine our expertise to launch a robust payment bank service in India. Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

dnaindia Saturday, May 21, 2016 7:16:00 AM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

reuters Friday, May 20, 2016 5:58:00 PM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw from setting up a payments bank, the licence will not be pursued," External link

dnaindia Friday, May 20, 2016 5:48:00 PM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

reuters-in Friday, May 20, 2016 5:36:00 PM EAT

Dilip Shanghvi said ( about Suzlon Energy ) : "While we believe Suzlon has the potential to emerge as a global leader in the renewable energy space from India, it will take substantial and sustained effort on part of the management team to achieve a significant operating performance improvement.," External link

economictimes Monday, February 16, 2015 10:27:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
billionaire6.50%EN09/13/201713/09/2017
managing director42.28%EN08/11/201711/08/2017
director24.39%EN08/11/201711/08/2017
directeur général8.13%FR01/05/201705/01/2017
tycoon9.76%EN11/23/201623/11/2016
owner0.81%EN07/17/201617/07/2016
founder2.44%EN06/08/201608/06/2016
chief executive1.63%EN05/31/201631/05/2016
chairman3.25%EN05/20/201620/05/2016
industries ceo0.81%EN03/03/201403/03/2014
Names Lang Count
Dilip ShanghviEN96.80%
Dilip ShanghviES1.60%
Dilip ShanghviDE0.80%
Dilip ShanghviFR0.80%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


Quotes... Extracted quotes about

AfricaBrief

Dilip Shanghvi

Last updated on 2015-03-06T08:47+0300.

About this image

sign

Quotes... Extracted quotes from

Dilip Shanghvi said : “So, that's broadly our understanding. So, we currently don't have any facility which we are looking at for producing vaccines,” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi said : “We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars,” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi noted : “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19” External link

Hindu Sunday, June 13, 2021 3:05:00 PM EAT

Dilip Shanghvi said : “So, that’s broadly our understanding. So, we currently don’t have any facility which we are looking at for producing vaccines,” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi said : “We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars,” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi noted : “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19” External link

financialexpress Sunday, June 13, 2021 11:42:00 AM EAT

Dilip Shanghvi said : “While our India business continues to outperform the average industry growth, our global specialty sales have continued to show an improving trend. Global Ilumya sales for the year have grown by 51 per cent to $143 million,” External link

economictimes Thursday, May 27, 2021 3:45:00 PM EAT

Dilip Shanghvi said : “Our Q3 performance reflects continued profitable business growth in a market that is gradually recovering from the impact of the global pandemic,” “Most of our businesses have done well over the third quarter last year” External link

Hindu Saturday, January 30, 2021 4:15:00 AM EAT

Dilip Shanghvi said : "It is a key determinant of the future growth and profitability of the specialty initiative. We expect to continue to invest in specialty R&D in the coming years as we progress further in building the specialty business," "Our R&D investments for the year were approximately Rs 20 billion. We continue to be disciplined in identifying future R&D projects for the US generics market and the focus is on developing differentiated generics. Investments for developing the long-term specialty pipeline are expected to continue" External link

siliconindia Monday, September 28, 2020 7:53:00 AM EAT

Dilip Shanghvi said : "We have also recently entered into an exclusive licensing and distribution agreement with Hikma Pharmaceuticals PLC for commercialisation of Ilumya in the Middle East and North Africa (MENA) region," External link

business-standard Sunday, September 27, 2020 10:29:00 AM EAT

Dilip Shanghvi said : "We expect this momentum to continue over the next few years, although the Covid-19 pandemic and lockdowns may throw up some uncertainties in the near-term," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : "We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : "Sun Pharma's strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space," External link

business-standard Tuesday, August 4, 2020 7:04:00 PM EAT

Dilip Shanghvi said : “We expect this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : “We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : “Sun Pharma’s strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space,” External link

financialexpress Tuesday, August 4, 2020 4:19:00 PM EAT

Dilip Shanghvi said : "We expect this momentum to continue over the next few years, although the COVID-19 pandemic and lockdowns may throw up some uncertainties in the near-term," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : "We have invested significant resources over the past few years in building this business and are now focusing on commercial execution to ensure that future cash flows justify these significant investments," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : "Sun Pharma's strong positioning in the global generics industry and continued investments for the future will ensure that it remains a prominent player in this space," External link

newindianexpress Tuesday, August 4, 2020 3:14:00 PM EAT

Dilip Shanghvi said : “We have not lost market share in any of the key products in the US or other markets. We witnessed the impact of lockdown on our US specialty business,” External link

business-standard Saturday, August 1, 2020 1:08:00 AM EAT

Dilip Shanghvi said : "Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients," "Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients," External link

timesofindia Friday, May 29, 2020 2:46:00 PM EAT

Dilip Shanghvi said : “We are committed to addressing these observations promptly,” External link

business-standard Thursday, February 6, 2020 10:04:00 PM EAT

Dilip Shanghvi said : “The focus is on developing relations with important players in that market (China) for our specialty products, and some generic products in which we do not expect much competition. As we continue to get approvals, China and Japan will become increasingly important” External link

business-standard Friday, November 8, 2019 12:53:00 AM EAT

Dilip Shanghvi said : “These are mostly products we are developing for other markets. Looking at the size of these markets, we do not rule out developing something specific for them,” External link

business-standard Friday, November 8, 2019 12:53:00 AM EAT

Dilip Shanghvi said : "We continue to focus on cost savings and efficiency improvement to align our generic business with the changing industry dynamics," External link

irishsun Thursday, November 7, 2019 4:06:00 PM EAT

Dilip Shanghvi said : "We continue to focus on cost savings and efficiency improvement to align our generic business with the changing industry dynamics," External link

business-standard Thursday, November 7, 2019 3:49:00 PM EAT

Dilip Shanghvi said ( about China Hong Kong ) : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and specialty portfolio. With more than 65 per cent generics penetration, China represents a significant opportunity for generic pharmaceutical companies,” External link

business-standard Wednesday, November 6, 2019 12:14:00 PM EAT

Dilip Shanghvi said : "This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio" External link

economictimes Monday, August 19, 2019 8:57:00 AM EAT

Dilip Shanghvi said : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio. With more than 65% generics penetration, China represents a significant opportunity for generic pharmaceutical companies,” External link

business-standard Friday, August 16, 2019 11:12:00 PM EAT

Dilip Shanghvi said : “This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio” External link

financialexpress Friday, August 16, 2019 9:04:00 PM EAT

Dilip Shanghvi said : "This collaboration gives us entry into the Chinese generic pharmaceutical market. We see lot of potential in China for both, our generics and speciality portfolio" External link

business-standard Friday, August 16, 2019 8:05:00 PM EAT

Dilip Shanghvi said : "This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline," "CSIR-IICT is well-known for its high-quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction," External link

business-standard Wednesday, August 14, 2019 12:49:00 PM EAT

Dilip Shanghvi said : “We have recorded growth across most of the markets for the quarter and our performance is in line with our full-year guidance. We are consistently focusing to ensure reasonable returns for our generics business. At the same time, we continue our unwavering efforts on building the specialty business,” External link

business-standard Tuesday, August 13, 2019 11:28:00 PM EAT

Dilip Shanghvi said : "We will look for a fresh recruitment for the branded business development function...," External link

business-standard Tuesday, August 13, 2019 8:30:00 PM EAT

Dilip Shanghvi said : "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance," "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance. We are consistently focusing on improving our efficiencies and cost structure to ensure reasonable returns for our generics business," External link

irishsun Tuesday, August 13, 2019 6:57:00 PM EAT

Dilip Shanghvi said : "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance," "We have recorded growth across most of the markets for the quarter and our performance is in-line with our full-year guidance. We are consistently focusing on improving our efficiencies and cost structure to ensure reasonable returns for our generics business," External link

business-standard Tuesday, August 13, 2019 5:28:00 PM EAT

Dilip Shanghvi said : "At the same time, we continue our unwavering efforts on building the specialty business and are encouraged by the potential of one of our pre-clinical research molecules which is likely to enter clinical trials next year," External link

business-standard Tuesday, August 13, 2019 5:28:00 PM EAT

Dilip Shanghvi said : "We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need," External link

business-standard Thursday, June 27, 2019 7:09:00 PM EAT

Dilip Shanghvi said : "In spite of the one-time impact for India business, our full year sales have grown by double digits" External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi said : "At the same time, we are strengthening our core operations, optimising the cost structure and enhancing our overall efficiencies," External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi said : “In spite of the one-time impact for India business, our full-year sales have grown by double digits. We continue to focus on executing our global speciality strategy. Ilumya (psoriasis drug) is expected to gradually gain traction in the US in FY20, while Cequa’s (ophthalmic drug’s) launch is expected in the coming months. At the same time, we are strengthening our core operations, optimising the cost structure and enhancing our overall efficiencies,” External link

business-standard Wednesday, May 29, 2019 12:16:00 AM EAT

Dilip Shanghvi says : “It does require some additional skills beyond what a typical generic has,” External link

business-standard Thursday, May 23, 2019 1:35:00 AM EAT

Dilip Shanghvi says : “The performance of many large multinational Big Pharma companies has been mixed,” External link

business-standard Thursday, May 23, 2019 1:35:00 AM EAT

Dilip Shanghvi said : “If I look at outcome then clearly that investment hasn’t had a great outcome,” External link

business-standard Wednesday, May 8, 2019 12:54:00 PM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

financialexpress Monday, May 6, 2019 10:35:00 AM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

financialexpress Monday, May 6, 2019 10:35:00 AM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

economictimes Sunday, May 5, 2019 2:16:00 PM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

economictimes Sunday, May 5, 2019 2:16:00 PM EAT

Dilip Shanghvi said : “There is a big opportunity for us,” External link

financialexpress Sunday, May 5, 2019 7:13:00 AM EAT

Dilip Shanghvi said : “We see enormous interest in China for products that we have global rights for,” External link

financialexpress Sunday, May 5, 2019 7:13:00 AM EAT

Dilip Shanghvi said : "While we do not have access to the whistleblower documents, we have received information request from SEBI related to our 2004 FCCB issuance and also for our transactions with Aditya Medisales. " External link

business-standard Wednesday, February 13, 2019 1:09:00 PM EAT

Dilip Shanghvi said : "The Ilumya launch in US has been well received by doctors. We recently commercialised Xelpros in the US and are preparing to launch Cequa in the coming months," External link

business-standard Tuesday, February 12, 2019 6:02:00 PM EAT

Dilip Shanghvi said : "Our focus on execution is reflected in the Q3 performance" External link

business-standard Tuesday, February 12, 2019 6:02:00 PM EAT

Dilip Shanghvi said : “The points raised by securities firm pertains to many information which are sourced from public domain and has been around for some time. Some of the issues are not related to Sun Pharma, some are incorrect, and some are old, as old as 15 years,” External link

economictimes Thursday, December 13, 2018 7:15:00 AM EAT

Dilip Shanghvi said : “Sun Pharma has not been involved in any insider trading of the Ranbaxy case. However there was a minor issue on the procedural aspect of trading window during a holiday” External link

economictimes Thursday, December 13, 2018 7:15:00 AM EAT

Dilip Shanghvi said : “The reason why we are suffering is our inability to execute,” External link

economictimes Saturday, August 12, 2017 9:51:00 AM EAT

Dilip Shanghvi said : "Our Q1 performance was not good ... due to the combined impact of increasing investments in our global specialty business, temporary disruption in our India business due to GST implementation, a challenging U.S. generic pricing environment and the Modafinil settlement," External link

reuters-in Friday, August 11, 2017 3:35:00 PM EAT

Dilip Shanghvi said : "We have followed the law in the U.S. and all our people have followed appropriate behaviour," External link

reuters-in Tuesday, February 14, 2017 9:00:00 PM EAT

Dilip Shanghvi said : "Looking at the experience of some other sites, it may take more than three months post-reinspection to get clearance," External link

reuters Thursday, November 10, 2016 7:30:00 PM EAT

Dilip Shanghvi said : "The synergies from the Ranbaxy acquisition are gaining momentum and we are on track to achieve the targeted benefits," External link

reuters Thursday, November 10, 2016 7:30:00 PM EAT

Dilip Shanghvi said : "Sun Pharma is committed to growing our dermatology franchise, with tildrakizumab as our lead investigational compound. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are proud to be partnering with a regional leader in dermatology, like Almirall, to bring tildrakizumab to the European market," External link

prnewswire Wednesday, July 27, 2016 9:20:00 PM EAT

Dilip Shanghvi said : “At Sun Pharma we are focused on offering quality medicines to all our customers and patients worldwide. Under the dynamic leadership of Prime Minister Modi, we see an environment of technology-led innovation in India. It will enable us to bring innovative products meeting unmet medical needs of patients globally,” External link

expressindia Wednesday, June 8, 2016 8:27:00 AM EAT

Dilip Shanghvi said ( about Narendra Modi ) : “At Sun Pharma we are focused on offering quality medicines to all our customers and patients worldwide. Under the dynamic leadership of Prime Minister Modi, we see an environment of technology-led innovation in India. It will enable us to bring innovative products meeting unmet medical needs of patients globally,” External link

4-traders Wednesday, June 8, 2016 3:22:00 AM EAT

Dilip Shanghvi said : "The intention of the JV was to combine our expertise to launch a robust payment bank service in India. Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

dnaindia Saturday, May 21, 2016 7:16:00 AM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

reuters Friday, May 20, 2016 5:58:00 PM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw from setting up a payments bank, the licence will not be pursued," External link

dnaindia Friday, May 20, 2016 5:48:00 PM EAT

Dilip Shanghvi said : "Following the mutual decision to withdraw these plans, the payment bank license will not be pursued," External link

reuters-in Friday, May 20, 2016 5:36:00 PM EAT

Dilip Shanghvi said ( about Suzlon Energy ) : "While we believe Suzlon has the potential to emerge as a global leader in the renewable energy space from India, it will take substantial and sustained effort on part of the management team to achieve a significant operating performance improvement.," External link

economictimes Monday, February 16, 2015 10:27:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
billionaire6.50%EN09/13/201713/09/2017
managing director42.28%EN08/11/201711/08/2017
director24.39%EN08/11/201711/08/2017
directeur général8.13%FR01/05/201705/01/2017
tycoon9.76%EN11/23/201623/11/2016
owner0.81%EN07/17/201617/07/2016
founder2.44%EN06/08/201608/06/2016
chief executive1.63%EN05/31/201631/05/2016
chairman3.25%EN05/20/201620/05/2016
industries ceo0.81%EN03/03/201403/03/2014
Names Lang Count
Dilip ShanghviEN96.80%
Dilip ShanghviES1.60%
Dilip ShanghviDE0.80%
Dilip ShanghviFR0.80%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Tuesday, August 3, 2021

12:59:00 PM EAT


Quotes... Explore Relations


EMM Visual Explorer


Quotes... Extracted quotes about